tetracyclines articles ↓

I came across the following graph in a recent presentation at the recent AAD meeting and figured it was interesting enough to highlight it here.

The following graph, sourced from Collagenex (who sell Oracea), shows the blood plasma concentration of doxycycline after taking Oracea compared to 50mg once a day of generic doxycycline. The horizontal axis stretches out to 24 hours post …

Some interesting comments from KUNC commentator Dr. Marc Ringel via a NPR segment. He raises two points that are worth discussing. Firstly is Oracea really any better than generic doxycycline and secondly what does it say about the pharmaceutical industry (and insurance companies – ed) that a repackaged old product  can be so expensive ? Galderma would say that …

Some very preliminary internet crumbs about a new possible rosacea treatment under development. The treatment under development is listed as a “novel tetracycline”. Warner Chilcott Limited calls itself a “specialty pharmaceutical company, that engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women’s healthcare and dermatology segments primarily in the United States”. In the WCRX 2007 Annual …

A recent investor presentation from Collagenex shows some interesting insights into how Collagenex are promoting Oracea. Oracea is promoted as safe and effective for long term use. It was reported that the average duration of Oracea therapy is 4 months, compared to an average of 2.5 months for other rosacea prescriptions. 52% of Oracea prescriptions are refills – the presentation suggests …

Despite promising looking Phase 1 and initial Phase 2 dose finding studies, Incyclinide will no longer be developed as a treatment for rosacea. Incyclinide is a chemically modified tetracycline that its developers – Collagenex, was hoping would become another systemic treatment for rosacea. We did get a warning in May that clinical trials for Incyclinide weren’t all going smoothly – when the …